NCT01326962View on ClinicalTrials.gov

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs or Anti-TNF

PHASE3CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

May 12, 2013

Study Completion Date

May 12, 2013

Conditions
Rheumatoid Arthritis
Interventions
DRUG

tocilizumab [RoActemra/Actemra]

8 mg/kg (max. 800 mg) iv every 4 weeks, 6 infusions

Trial Locations (4)

11525

King Fahad Medical City; Gastroentrology, Riyadh

21589

King Abdulaziz University Hospital, Jeddah

31444

King Fahad Specialist Hospital; Oncology, Dammam

Unknown

Heraa General Hospital; Rheumatology, Mecca

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01326962 - A Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs or Anti-TNF | Biotech Hunter | Biotech Hunter